Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC ...

A Watertown biotech is suspending drug development and laying off essentially all of its workers in a bid to save cash and ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

Despite an unusual lack of major announcements, energy is high. And a few key themes dominate discussions.

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA.

International pharmaceutical leaders and investors gathered in San Francisco on Sunday to explore partnership opportunities ...

Former Pfizer, BenevolentAI, Incyte, and AMAG executives join to strengthen clinical, technology, financial, and scientific leadership as company scales its AI-native pharma model Together, these ...

Explore key identity management challenges in pharma and biotech SaaS platforms and learn practical solutions for security, ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...